Articles with public access mandates - Missak Haigentz, MDLearn more
Not available anywhere: 3
Salivary mucoepidermoid carcinoma revisited
A Coca-Pelaz, JP Rodrigo, A Triantafyllou, JL Hunt, A Rinaldo, P Strojan, ...
European Archives of Oto-Rhino-Laryngology 272, 799-819, 2015
Mandates: Government of Spain
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib
YH Ling, T Li, R Perez-Soler, M Haigentz
Cancer chemotherapy and pharmacology 64, 539-548, 2009
Mandates: US National Institutes of Health
Waiting for big changes in limited-stage small-cell lung cancer: for now, more of the same
MP Deek, M Haigentz, SK Jabbour
Journal of Clinical Oncology 41 (13), 2326-2330, 2023
Mandates: US National Institutes of Health
Available somewhere: 23
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ...
The Lancet Oncology 19 (4), 521-536, 2018
Mandates: US National Institutes of Health
Update on primary head and neck mucosal melanoma
F López, JP Rodrigo, A Cardesa, A Triantafyllou, KO Devaney, ...
Head & neck 38 (1), 147-155, 2016
Mandates: US National Institutes of Health
Cervical lymph node metastases from remote primary tumor sites
F López, JP Rodrigo, CE Silver, M Haigentz Jr, JA Bishop, P Strojan, ...
Head & neck 38 (S1), E2374-E2385, 2016
Mandates: US National Institutes of Health
Combined P16 and human papillomavirus testing predicts head and neck cancer survival
CR Salazar, N Anayannis, RV Smith, Y Wang, M Haigentz Jr, M Garg, ...
International journal of cancer 135 (10), 2404-2412, 2014
Mandates: US National Institutes of Health
Lung cancer in HIV infection
D Mani, M Haigentz Jr, DM Aboulafia
Clinical lung cancer 13 (1), 6-13, 2012
Mandates: US National Institutes of Health
Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer
M Haigentz Jr, M Kim, C Sarta, J Lin, RS Keresztes, B Culliney, AG Gaba, ...
Oral oncology 48 (12), 1281-1288, 2012
Mandates: US National Institutes of Health
Phase III randomized trial of chemotherapy with or without bevacizumab in patients with recurrent or metastatic head and neck cancer
A Argiris, S Li, P Savvides, JP Ohr, J Gilbert, MA Levine, A Chakravarti, ...
Journal of Clinical Oncology 37 (34), 3266-3274, 2019
Mandates: US National Institutes of Health
Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment
CR Salazar, RV Smith, MK Garg, M Haigentz, BA Schiff, N Kawachi, ...
Head and neck pathology 8, 77-87, 2014
Mandates: US National Institutes of Health
Continuous activity monitoring during concurrent chemoradiotherapy
N Ohri, R Kabarriti, WR Bodner, KJ Mehta, V Shankar, B Halmos, ...
International Journal of Radiation Oncology* Biology* Physics 97 (5), 1061-1065, 2017
Mandates: US National Institutes of Health
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma
J Gilbert, MJ Schell, X Zhao, B Murphy, T Tanvetyanon, ME Leon, ...
Oral oncology 51 (4), 376-382, 2015
Mandates: US National Institutes of Health
Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: pathophysiology and management
SE Abdullah, M Haigentz Jr, B Piperdi
Chemotherapy research and practice 2012 (1), 351210, 2012
Mandates: US National Institutes of Health
Phase II 2‐arm trial of the proteasome inhibitor, PS‐341 (bortezomib) in combination with irinotecan or PS‐341 alone followed by the addition of irinotecan at time of …
J Gilbert, JW Lee, A Argiris, M Haigentz Jr, LE Feldman, M Jang, P Arun, ...
Head & neck 35 (7), 942-948, 2013
Mandates: US National Institutes of Health
A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus‐positive patients with cancer: AIDS …
MA Rudek, PC Moore, RT Mitsuyasu, BJ Dezube, D Aboulafia, ...
Cancer 120 (8), 1194-1202, 2014
Mandates: US National Institutes of Health
Targeting the EGFR and immune pathways in squamous cell carcinoma of the head and neck (SCCHN): forging a new alliance
NF Saba, ZG Chen, M Haigentz, P Bossi, A Rinaldo, JP Rodrigo, ...
Molecular cancer therapeutics 18 (11), 1909-1915, 2019
Mandates: US National Institutes of Health
Current questions in HIV-associated lung cancer
M Shcherba, J Shuter, M Haigentz Jr
Current opinion in oncology 25 (5), 511-517, 2013
Mandates: US National Institutes of Health
AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma
CD Fulcher, M Haigentz Jr, TJ Ow, ...
Head & neck 40 (4), 676-686, 2018
Mandates: US National Institutes of Health
Risk of cancer among commercially insured HIV‐infected adults on antiretroviral therapy
JY Lee, I Dhakal, C Casper, A Noy, JM Palefsky, M Haigentz, SE Krown, ...
Journal of Cancer Epidemiology 2016 (1), 2138259, 2016
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program